



Chandel, N., Ayosolla, K., Wen, H., Lan, X., Haque, S., Saleem, M. A., Malhotra, A., & Singhal, P. C. (2017). Vitamin D Receptor Deficit Induces Activation of Renin Angiotensin System Via SIRT1 Modulation in Podocytes. *Experimental and Molecular Pathology*, 102(1), 97-105. <https://doi.org/10.1016/j.yexmp.2017.01.001>

Peer reviewed version

License (if available):  
CC BY-NC-ND

Link to published version (if available):  
[10.1016/j.yexmp.2017.01.001](https://doi.org/10.1016/j.yexmp.2017.01.001)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at <https://doi.org/10.1016/j.yexmp.2017.01.001> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Vitamin D Receptor Deficit Induces Activation of Renin Angiotensin System  
Via SIRT1 Modulation in Podocytes

Nirupama Chandel<sup>1</sup>, Hongxiu Wen<sup>1</sup>, Xiqian Lan<sup>1</sup>, Shabirul Haque<sup>1</sup> Moin A. Saleem<sup>2</sup>,  
Ashwani Malhotra<sup>1</sup>, and Pravin C. Singhal<sup>1</sup>

<sup>1</sup>Department of Medicine, Hofstra North Shore LIJ Medical School and Feinstein  
Institute for Medical Research New York, and <sup>2</sup> Renal Academic Unit, University of Bristol,  
UK.

Address for correspondence:  
Pravin C. Singhal, MD  
100 Community Drive  
Great Neck, NY 11021  
Tel 516-465-3010  
Fax 516-465-3011  
Running Head: VDR negatively regulates RAS

## Abstract

Vitamin D receptor (VDR) deficient status has been shown to be associated with the activation of renin angiotensin system (RAS). We hypothesized that lack of VDR would enhance p53 expression in podocytes through down regulation of SIRT1; the former would enhance the transcription of angiotensinogen (Agt) and angiotensinogen II type 1 receptor (AT1R) leading to the activation of RAS. Renal tissues of VDR mutant (M) mice displayed increased expression of p53, Agt, renin, and AT1R. *In vitro* studies, VDR knockout podocytes not only displayed up regulation p53 but also displayed enhanced expression of Agt, renin and AT1R. VDR deficient podocytes also displayed an increase in mRNA expression for p53, Agt, renin, and AT1R. Interestingly, renal tissues of VDR-M as well as VDR heterozygous (h) mice displayed attenuated expression of deacetylase SIRT1. Renal tissues of VDR-M mice showed acetylation of p53 at lysine (K) 382 residues inferring that enhanced p53 expression in renal tissues could be the result of ongoing acetylation, a consequence of SIRT1 deficient state. Notably, podocytes lacking SIRT1 not only showed acetylation of p53 at lysine (K) 382 residues but also displayed enhanced p53 expression. Since renal tissues of VDR-M mice also showed enhanced expression of PPAR- $\gamma$ , it is plausible that either the deficit of SIRT1 has de-repressed expression of PPAR- $\gamma$  or enhanced podocyte expression of PPAR- $\gamma$  (in the absence of VDR) has contributed to the down regulation of SIRT1. Based on our experimental data, we conclude that VDR deficit activates the RAS via SIRT1 modulation.

53

54 Vitamin D has been demonstrated to be a negative regulator of renin (20). Interestingly,  
55 VDR knockout mice have also been demonstrated to activate Renin Angiotensin  
56 System (RAS) without displaying a vitamin D deficient state (20). These mice developed  
57 hypertension and cardiac hypertrophy as a consequence to the activation of the RAS  
58 (31). However, levels of angiotensinogen (Agt) and AT1R mRNA were not altered in  
59 cardiac myocytes. Contrary to these findings, renal tissues of VDR knockout diabetic  
60 mice displayed enhanced renin and Agt expression (34). We hypothesized that lack of  
61 VDR would modulate the transcription of the Agt and AT1R in kidney cells of VDR  
62 knockout mice. Further, these effects of VDR deficit status could be mediated through  
63 attenuated Human Silent Information Regulator Type (SIRT) 1 resulting into enhanced  
64 p53 expression by kidney cells.

65 SIRT1 is a NAD<sup>+</sup>-dependent deacetylase that regulates cell phenotype including  
66 cell death/survival, senescence, and metabolism (3). It is involved in transcriptional  
67 silencing of genes by chromatin modification via histone deacetylation, DNA damage  
68 response, and life span extension secondary to calorie restriction (5, 15, 30). SIRT1 is  
69 also a repressor of nuclear receptors such as PPAR $\gamma$  by docking with co-repressors -  
70 nuclear receptor corepressor (NCoR1) and silencing mediator for retinoid or thyroid-  
71 hormone receptors (SMRT, NCoR2) (21). Interestingly, SIRT1 negatively regulates p53  
72 expression by deacetylating p53 in response to DNA damage (2, 27, 29). Conversely,  
73 elevation of cellular p53 expression enhances expression of SIRT1 as a negative  
74 feedback.

75           Recently, liganded VDR has been shown to modulate expression of FOXO3a  
76 target genes through deacetylation of FOXO3A via SIRT1 in SCC25 cells (4). In these  
77 studies, lack of VDR as well as SIRT1 was associated with phosphorylation of FOXO3a.  
78 In the present study, we have evaluated the effect of VDR down regulation on podocyte  
79 SIRT1 expression and associated up regulation of p53 expression.

80           We and other investigators previously reported the role of p53 in the transcription  
81 of angiotensinogen and AT1 receptors in cardiac myocytes in high glucose milieu (18).  
82 These effects of p53 were associated with the activation of renin angiotensin system  
83 and cardiac myocyte hypertrophy (18). However, in these studies the role of VDR and  
84 SIRT1 was not explored. We have recently reported that high glucose down regulated  
85 podocyte VDR expression both *in vitro* and *in vivo* studies (24). In these studies, high  
86 glucose-induced down regulation of VDR was associated with the activation of the RAS.  
87 However, we did not explore the role of SIRT1 and p53 in the induction of activation of  
88 the RAS in podocytes.

89           In the present study, we evaluated the effect of lack of VDR from the genome of  
90 kidney cells on SIRT1 expression both *in vivo* and *in vitro* studies. We delineated the  
91 involved molecular mechanisms of the activation of renin angiotensin system in  
92 podocytes lacking VDR.

## **Material and Methods**

### **VDR Mutant mice**

VDR<sup>tm1MBD+/-</sup> were purchased from Jackson Laboratories (Bar Harbor, Maine), and bred to develop homozygous VDR mutant (VDR-M, VDR<sup>tm1MBD+/+</sup> mice) on FVB/N background.

### **Human podocytes**

Human podocytes (HPs) were obtained from Dr. Moin A. Saleem (Children's renal unit and academic renal unit, University of Bristol, Southmead Hospital, Bristol, UK). Human podocytes were conditionally immortalized by introducing temperature-sensitive SV40- T antigen by transfection. The cells have additionally been transfected with a human telomerase construct. These cells proliferate at permissive temperature (33°C, conditionally immortalized human podocytes) and enter growth arrest (conditionally immortalized differentiated human podocytes) after transfer to the non-permissive temperature (37°C). The growth medium contains RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1x Pen-Strep, 1 mM L-glutamine and 1x ITS (Invitrogen) to promote expression of T antigen. Since incubation media being deficient (contained only 10% serum) in vitamin D, majority of podocyte VDR was unliganded.

### **Silencing for VDR and SIRT1**

HPs were transfected with 25 nM VDR siRNA, control-siRNA (Santa Cruz Biotechnology, Santa Cruz, CA), or SIRT1 siRNA (Cell Signaling) with Siport Neofax

transfection reagent and left in optiMEM media for 48 hrs. Control and transfected cells were used under control and experimental conditions.

### **Western blotting studies**

Protein blots of control and experimental cells/renal tissues were processed as described previously (9). Nitrocellulose membranes were then processed further for immunostaining with primary antibodies against SIRT1 (anti-rabbit, Santa Cruz Biotechnology, Santa Cruz, CA), p53 (antimouse, Abcam, Cambridge, San Francisco, CA), Ac<sup>k382</sup>-p53 (anti-rabbit, Abcam), angiotensinogen (anti-rabbit, Abcam), AT1R (anti-rabbit, Santa Cruz), renin (Santa Cruz), or PPAR- $\gamma$  (anti-rabbit, Cell Signaling, Danvers, MA) and subsequently with horseradish peroxidase (HRP) labeled appropriate secondary antibodies. The blots were developed using a chemiluminescence detection kit (PIERCE, Rockford, IL) and exposed to X-ray film (Eastman Kodak Co., Rochester, NY). Equal protein loading and the protein transfer were confirmed by immunoblotting for determination of actin protein using a polyclonal  $\alpha$ -Actin antibody (I-19, Santa Cruz, CA) on the same (stripped) Western blots.

### **Reverse Transcription PCR Analysis**

Control and experimental podocytes were used to quantify mRNA expression of VDR, p53, renin, Agt, AT1R, and SIRT1 as described previously (15). Quantitative PCR was carried out in an ABI Prism 7900HT sequence detection system using the primer sequences as shown below:

#### **VDR (Human)**

5 : GACTTTGACCGGAACGTGCCC -3

137 5: CATCATGCCGATGTCCACACA -3

138 **Agt (Human)**

139 F: 5-CTGCAAGGATCTTATGACCTGC-3

140 R: 5-TACACAGCAAACAGGAATGGGC-3

141 **Renin (Human)**

142 F: 5-AAATGAAGGGGGTGTCTGTGG-3

143 R: 5-AAGCCAATGCGGTTGTTAACGC-3

144 **SIRT1 (Human)**

145 F:5'-CAGGTTGCGGGAATCCAAAG-3'

146 R:5'-GCTGGGCACCTAGGACATCG-3'

147 SYBR green was used as the detector and ROX as a stabilizing dye. Results (means  $\pm$   
148 S.D.) represent number of samples as described in the legend. The data was analyzed  
149 using the Comparative  $C_T$  method ( $\Delta\Delta^{CT}$  method). Differences in  $C_T$  are used to quantify  
150 relative amount of PCR target contained within each well. The data was expressed as  
151 relative mRNA expression with reference to control, normalized to quantity RNA input  
152 by performing measurements on an endogenous reference gene, GAPDH.

153 **Statistical analysis**

154 For comparison of mean values between two groups, the unpaired t test was  
155 used. To compare values between multiple groups, analysis of variance (ANOVA) was  
156 applied and a Bonferroni multiple range test was used to calculate a P-value. Statistical  
157 significance was defined as  $P < 0.05$ . All values are displayed as mean  $\pm$  SD.

158



## **Results**

### **Renal tissues lacking VDR display enhanced expression of p53 and activation of renin angiotensin system**

Since p53 is known to enhance cardiac myocyte expression of angiotensinogen and AT1R expression (18) we asked whether renal tissues of VDR-M would display enhanced expression of p53 and associated downstream signaling. Protein blots of renal tissues of control and VDR mutant mice were probed for p53, angiotensinogen (Agt), renin, and AT1R and reprobed for actin (n=4). Representative gels in duplicate are displayed in Fig 1A. Cumulative densitometric data (n=4) are shown as bar graphs. VDR lacking renal tissues displayed 8 fold increases in p53 expression when compared to control mice (Fig. 1B). Renal tissues from VDR mutant mice displayed 3 fold increase in Agt expression (Fig. 1C), 2 fold increase in renin expression (Fig. 1D), and 5-fold increase in AT1R expression (Fig. 1E). These findings indicate that lack of VDR in these mice is associated with an upregulation of renal tissue p53 expression leading to the activation of renin angiotensin system.

### **VDR deficient podocytes display enhanced expression of p53 and activation of renin angiotensin system**

To confirm the effect of the lack of VDR on podocyte p53 expression and associated activation of the RAS, podocytes were partially silenced for VDR. Podocytes were either silenced for VDR by transfecting them with siRNA-VDR or control (scrambled)-siRNA. Protein blots of SiCon/HPs or SiVDR/HPs (n=4) were probed for p53 and then reprobed for Agt, renin, and actin. Representative gels (in duplicates) are shown in Fig.

2A. Cumulative densitometric data are shown as bar graphs. siRNA/HPs displayed down regulation of VDR expression by 50% when compared to siCon/HPs (Fig. 2B). VDR deficient podocytes showed 1.8 fold increase in their p53 expression (Fig, 2C) and similar increase in Agt (Fig. 2D) and renin (Fig 2E) expressions.

To determine the effect of podocyte VDR silencing on the transcription of VDR, p53, and molecules involved in the RAS, podocytes were transfected with either scrambled SiRNA (SiCon) or SiRNA-VDR (SiVDR). cDNAs from siCon and SiVDR were amplified with specific primers for VDR, p53, Agt and renin. Transfection of HPs with SiVDR decreased VDR expression in podocytes by 50% (Fig. 3A). This decrease in podocyte VDR transcription was associated with increased p53 transcription only by 25% (data not shown). Nonetheless there was a significant increase in p53 protein expression (Fig. 2C) in podocyte lacking VDR. Increased functionality of p53 in podocytes silenced for VDR was further confirmed by display of enhanced transcription of both Agt (Fig. 3B) and renin (Fig. 3C) by approximately two fold.

#### **Lack of VDR is associated with down regulation of SIRT1 in VDR-M mice**

SIRT1 is a deacetylase and modulates p53 expression through deacetylation (3, 5). On that account, lack of SIRT1 has been reported to enhance p53 expression (29). We asked whether lack of VDR is associated with down regulation of SIRT1. Protein blots of renal tissues (n=4) of control and VDR-M mice were probed for SIRT1 and the same blots were reprobed for GAPDH. Representative gels are displayed in Fig. 4A. Renal tissues of VDR-M mice displayed attenuated expression of SIRT1. Since renal tissues of VDR-M mice barely displayed any expression of SIRT1, we also evaluated renal

tissue SIRT1 expression in VDR-heterozygous mice (h). Protein blots of renal tissues of control (n=4) and VDR-H (n=5) were probed for SIRT1 and reprobed for GAPDH. Gels are displayed in Fig. 4B. Densitometric data are shown as bar graphs in Fig. 4C. Renal tissues of VDR-h mice displayed attenuated expression of SIRT1.

### **p53 acetylation at lysine (K) 382 residues is prevailed in renal tissues lacking VDR**

Since acetylation of p53 at k382 residues has been shown to be associated with enhanced p53 expression, we expected lack of VDR in renal tissues would also be associated with acetylation p53 at K382 residues. Renal tissues of control (n=3) and VDR-M (n=3) were probed for SIRT1. The same blots were stripped and reprobed for p53, Ac<sup>k382</sup>-p53, Agt, AT1R, PPAR-γ, and GAPDH. Gels are displayed in Fig. 5. Renal tissues of VDR-M mice displayed attenuated expression of SIRT1 but enhanced expression of p53 and acetylation at the 382 residue site. These findings indicate that down regulation of SIRT1 in mice lacking VDR may be enhancing p53 expression through acetylation at K382 residues. Renal tissues of VDR-M mice also displayed enhanced expression of Agt and AT1R. Interestingly, renal tissues of VDR-M mice displayed enhanced expression of PPAR-γ. Since SIRT1 is a component of PARP-γ repressor complex, lack of SIRT1 is likely to disrupt repressor complex (21).

### **Podocytes partially lacking SIRT1 from their genome display enhanced acetylation of p53 at K382 residues in podocytes**

Since SIRT1 is a deacetylase, we asked whether partial deficit of SIRT1 from the genome of podocytes would enhance acetylation of p53 at K382 residues. Human

podocytes were transfected either control (C )- siRNA or SIRT1-siRNA. Control cells, C-siRNA- and SIRT1-siRNA transfected cells were incubated in media for 24 hours and extracted for protein and RNA.

cDNAs were prepared and amplified with a probe specific for SIRT1. Results are displayed in Fig. 6A. Podocytes transfected with SIRT1-siRNA displayed 50% down regulation of SIRT1 mRNA expression.

Protein blots were probed for SIRT1, p53, ac-k382p53, and GAPDH. Gels are displayed in Fig. 6B. Podocytes- transfected with SIRT1-siRNA displayed modest down regulation (30% only) of SIRT1 protein expression. Nonetheless, podocytes transfected with SIRT1-siRNA displayed both robust acetylation of p53 at K382 residues and an increased p53 protein expression. Thus, it appears that despite 50% down regulation of SIRT1 gene expression in the genome of podocytes, protein expression of SIRT1 in SIRT1-siRNA transfected podocytes was not reduced to the same magnitude. We would like to clarify this discrepancy in mRNA and protein expression of SIRT1 in these studies. Downstream signaling in the form of robust increase in p53 acetylation at K382 residues as well as abundant p53 protein expression confirmed the deficit in functionality of SIRT1 in these podocytes. We speculate that sustained increase in podocyte expression of p53 stimulated SIRT1 expression in podocytes partially lacking SIRT1 from their genome as a negative feedback. Moreover, these findings are consistent with the observations of other investigators (5, 15).

**High Glucose milieu down regulates SIRT1, enhances p53 acetylation and RAS activation**

We and other investigators have previously reported down regulation of podocyte VDR expression in adverse milieus both *in vitro* and *in vivo* studies (8, 9, 25, 26, 34). We asked whether high glucose milieu would also down regulate SIRT1 and enhance podocyte p53 expression and associated downstream signals. Human podocytes were incubated in media containing either normal glucose (5 mM, control) or high glucose (35 mM) for 24 and 48 hours. Protein blots were probed for SIRT1. The same blots were reprobed for p53, Agt, and GAPDH. Gels are displayed in Fig. 7A. High glucose attenuated podocyte SIRT1 expression but enhanced expression of both p53 and Agt at 24 hours. However, after 48 hours SIRT1 expression is also up regulated when compared to 24 hours treatment. However, these findings are consistent with the other investigators indicating that in due course of time elevated levels of p53 would also enhance SIRT1 expression as a negative feedback (as mentioned above, Fig. 6B; 5, 6). Therefore, acetylation of p53 and its expression is the determinant of functionality of the SIRT1.

To determine the time course effect of high glucose on podocyte SIRT1 and p53 expression, human podocytes (HPs) were incubated in media containing either normal glucose (5 mM) or high glucose (35 mM) for variable time periods (4, 12, 24, and 48 hours). Protein blots were probed for SIRT1. The same blots were reprobed for p53 and GAPDH. Gels are displayed in Fig. 7B. High glucose down regulated SIRT1 expression up to 24 hours. However, it is normalized to some extent as a negative feedback at 48 hours. Conversely, p53 expression was upregulated up to 24 hours and then declined at 48 hours. These findings further support the involved dynamics in SIRT1 and p53 expression, which are consistent both under physiological and pathological states.

270

271 **Enhanced podocyte VDR expression is associated with increased SIRT1**

272 **expression**

273 Since down regulation of VDR modulated podocyte SIRT1 expression, we expected  
274 enhanced podocyte VDR expression would be associated with enhanced SIRT1  
275 expression. To determine the effect of enhanced podocyte VDR expression on SIRT1  
276 expression, podocytes were transfected with control plasmid (pcDNA), SIRT1, or VDR.  
277 In parallel sets of experiments podocytes were incubated in media containing VDR  
278 agonist (VDA, EB1089, 1 nM) for 24 hours. Protein blots were probed for SIRT1 and  
279 reprobed for GAPDH. Gels are displayed in Fig. 8A. Podocytes transfected with VDR  
280 or treated with VDA displayed enhanced expression of SIRT1.

281 To determine the time course effect of VDA on podocyte SIRT1 expression, podocytes  
282 were incubated in media containing VDA (EB1089, 1 nM) for variable time periods (0,  
283 2,4, 8, 12, 24 hours). Protein blots were probed for SIRT1 and reprobed for GAPDH.  
284 VDA enhanced SIRT1 expression as early as 2 hours (Fig. 8B).

285 Proposed scheme depicting the role of VDR in the activation of the RAS is shown in Fig.  
286 9. Lack of VDR in podocytes induces down regulation of SIRT1, which enhances  
287 podocyte p53 expression through allowing acetylation of p53. Enhanced p53 expression  
288 induces transcription of Agt and AT1R leading to the activation of the RAS.

## Discussion

VDR knockout mice have been demonstrated to activate RAS as well as its downstream effects in the form of cardiac hypertrophy (31). It was suggested that the activation of the RAS was a consequence of disruption of vitamin D and VDR nexus (20). In the present study, we determined that lack of VDR was associated with enhanced expression of angiotensinogen and AT1 by renal tissues as well as by podocytes. This effect of VDR deficit seems to be mediated by enhanced expression of p53 both in renal tissues and podocytes. Occurrence of acetylation of p53 at K382 residues contributed to enhanced expression of p53 in renal tissues lacking SIRT1.

Recently, high Ang II states including high glucose and HIV milieus have been reported to cause down regulation of VDR in podocytes (8, 9, 25, 26, 34). High Ang II states down regulate podocyte VDR by multiple mechanisms including enhanced VDR degradation via proteasomal pathway and through transcription of CYP24A via de-repression of co-repressor complexes at CYP24A1 promoter (26). Since CYP24A1 metabolizes vitamin D, enhanced podocyte CYP24A1 state would be associated with low vitamin D which would lead to the accelerated degradation of VDR. Additionally, Ang II as well as conditions associated with high Ang II states such as high glucose and HIV milieus are associated with enhanced podocyte expression of SNAIL (19, 32); the latter is a repressor of transcription of VDR (17, 32). Knocking of VDR in kidney cells has been demonstrated to enhance the activation of renin angiotensin system (RAS) (8,9,25, 26, 34). Thus, it appears that Ang II perpetuates its production through down regulation of VDR in kidney cells.

We have previously reported that high glucose enhanced kidney cell p53 and angiotensinogen expression in podocytes (28). We and other investigators also demonstrated similar phenomenon in cardiac myocytes (18). In the present study, we asked whether high glucose induced activation of the RAS is mediated through down regulation of SIRT1 and upregulation of p53. SIRT1 is a negative regulator of p53 because of its deacetylase activity (3); conversely, p53 enhances SIRT1 expression as a negative feedback (5, 15). Because of this complex inter-relationship between these molecules, downstream functionality in the form of p53 acetylation or p53 expression seems to be a better marker of SIRT1 activity rather than to mere SIRT1 protein expression. In the present study too, podocytes partially silenced for SIRT1 displayed robust acetylation of p53 and abundant expression p53 and thus confirming a deficit in functionality of SIRT1. Since p53 was in abundance it is likely to increase expression of SIRT1 in these cells, as negative feedback. As expected, despite lack of SIRT1 in the genome of these podocytes, these cells displayed moderate SIRT1 expression. This aspect was better exemplified in time course effect of high glucose on podocyte SIRT1 expression. High glucose attenuated podocyte SIRT1 expression but enhanced p53 expression during early time period (up to 24 hours); however, at 48 hours, podocyte SIRT1 expression was up regulated and p53 expression diminished partially. These findings highlight ongoing dynamic relationship between these molecules during sustained exposure of adverse milieus.

SIRT1 protein directly interacts with PPAR $\gamma$  to form a complex and may thus control acetylation and deacetylation status of PPAR $\gamma$  (13, 23). PPAR $\gamma$  also binds to the promoter of *SIRT1* gene and control the expression *SIRT1* gene (23). Thus, both



PPAR $\gamma$  and SIRT1 inversely regulate each other's expression. The involved mechanism of SIRT1 down regulation in cells lacking VDR is very well understood to date. Both VDR and PPAR $\gamma$  compete for binding with RXR for their functionality (1). Therefore, PPAR- $\gamma$  binding with RXR will go unchallenged in cells lacking VDR. Since PPAR $\gamma$  negatively regulates SIRT1 expression, it would down regulate SIRT1 expression in conditioned cells lacking VDR. Additionally, SIRT1 is also a part of PPAR- $\gamma$ -RXR repressor complex docking on DNA binding site of PPRE (21); therefore, lack of SIRT1 would disrupt the repressor complex and de-repress the target gene expression such as PPAR- $\gamma$ . In the present study, renal tissues lacking VDR displayed enhanced expression of PPAR $\gamma$  and attenuated expression of SIRT1. We speculate that either PPAR $\gamma$  would be contributing to down regulation of SIRT1 expression in podocytes lacking VDR or lack of SIRT1 de-repressing the expression of PPAR $\gamma$ . It would be worth while exploring this aspect of the investigation in our future studies.

p53 is normally maintained at a low concentration in quiescent cells by continuous ubiquitination and proteasome-mediated degradation (6). However, p53 expression gets up regulated in cells under stress because of suppression of p53 ubiquitination and enhancement of p53 acetylation. Under stress, SIRT1, a deacetylase of p53 is destabilized and degraded via proteasomal pathway (7). Reduction of deacetylation of p53 leads to the acetylation of p53 (33). On the other hand, up regulation of SIRT1 inactivates p53 (3, 5). In the present study, renal tissues of VDR mutant mice as well as VDR-silenced podocytes displayed enhanced expression of podocyte p53. Since lack of VDR in renal tissues was not only associated with down regulation of SIRT1 but was also associated with acetylation of p53 at 382 residues of

renal tissues, it is likely upregulation of p53 expression was contributed by lack of SIRT1 to some extent.

Deficiency of vitamin D has been incriminated a variety of chronic diseases including tuberculosis (16), HIV (10), hypertension (12), colon cancer (11) and chronic kidney diseases (22). However, outcome of clinical trials of vitamin D therapy in clinical trials of disease has not shown very promising data (14). Since vitamin D worked through VDR, functionality of vitamin D could be better be monitored by VDR status. It has been shown in patients of colon cancer that vitamin D receptor could not be optimally raised with vitamin D therapy in several instances and these patients did not respond to vitamin D therapy (17). We have recently reported that HIV down regulated podocyte VDR expression thorough CpG methylation at VDR promoter (8). In these studies, Vitamin D could not up regulate podocyte VDR expression optimally; however, use of a demethylating agent in combination with vitamin D could optimally increase podocyte VDR expression in HIV milieu (8). We propose that discrepancy in vitamin D clinical trials may be related to the inability of vitamin D in upregulating VDR optimally because of the down regulation as a consequence of epigenetics. It will be worth investing this aspect of investigation in future studies.

Vitamin D has been reported to be a negative endocrine regulator of renin transcription (20). This effect of vitamin D has been attributed to liganded-VDR which blocks the binding of CRP binding protein (CBP) at renin promoter and thus preventing the transcription of renin. On that account, vitamin D is being used to down regulate renin angiotensin system in patients of chronic kidney diseases (22). In the present study, we observed that lack of unliganded- VDR enhances transcription of several

381 molecules involved in the activation of the RAS. During vitamin D deficient state, there  
382 is a reduction of total VDR because of decreased transcription of VDR and enhanced  
383 degradation of unliganded VDR (See Scheme in Fig. 10). Thus, vitamin D deficient  
384 status is associated with a decrease in both unliganded (UL) and liganded (L) VDR. In  
385 this scenario, lack of liganded VDR would sustain the transcription of renin, whereas,  
386 lack of unliganded VDR would enhance transcription of angiotensinogen and AT1R via  
387 modulation of p53 expression. Theoretically, unliganded VDR-induced AT1R activation  
388 should down regulate renin gene expression; however, this negative feedback effect of  
389 AT1R activation is likely be nullified or neutralized because of deficient liganded VDR  
390 mediated-enhanced renin transcription. Thus, it appears that lack of VDR or VDR  
391 deficient state has multiple ways to activate the RAS.

392 In conclusion, we report for the first time that lack of VDR in the genome kidney  
393 cells enhances expression of p53 via down regulation of SIRT1 resulting into enhanced  
394 transcription of Agt and AT1R that further leads to the activation of the RAS.

396 **Acknowledgement**

397 This work was supported by grant RO1DK084910, RO1 DK083931, and  
398 1R01DK098074 (PCS) from National Institutes of Health, Bethesda, MD.

399

400

401

402 **References**

- 403       1. Alimirah F, Peng X, Yuan L, Mehta RR, von Knethen A, Choubey D, Mehta RG.  
404       Crosstalk between the peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) and  
405       the vitamin D receptor (VDR) in human breast cancer cells: PPAR $\gamma$  binds to VDR  
406       and inhibits 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> mediated transactivation.Exp Cell Res.  
407       2012 Nov 15;318(19):2490-7.
- 408       2. Appella E, Anderson CW. Post-translational modifications and activation of p53  
409       by genotoxic stresses. Eur J Biochem. 2001;268:2764–2772.
- 410       3. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1  
411       activation prevent axonal degeneration. Science. 2004;305:1010–1013.
- 412       4. Beum-Soo An, Luz E. Tavera-Mendoza, Vassil Dimitrov, Xiaofeng Wang, Mario  
413       R. Calderon, Hui-Jun Wang, John H. White. Stimulation of Sirt1-  
414       regulated FoxO Protein Function by the Ligand-Bound Vitamin D Receptor Mol  
415       Cell Biol. 2010 October; 30(20): 4890–4900.
- 416       5. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and  
417       cancer. Nat Rev Cancer. 2009;9:123–128.
- 418       6. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular  
419       basis for p53 regulation. Curr Opin Cell Biol. 2003;15:164–171.
- 420       7. Caito S, Rajendrasozhan S, Cook S, Chung S, Yao H, Friedman AE, Brookes  
421       PS, Rahman I. SIRT1 is a redox-sensitive deacetylase that is post-translationally  
422       modified by oxidants and carbonyl stress.FASEB J. 2010, 24(9): 3145–3159.

8. Chandel N, Ayasolla KS, Lan X, Sultana-Syed M, Chawla A, Lederman R, Vethantham V, Saleem MA, Chander PN, Malhotra A, Singhal PC. Epigenetic Modulation of Human Podocyte Vitamin D Receptor in HIV Milieu. *J Mol Biol.* 2015, 427(20):3201-15.
9. Chandel N, Sharma B, Husain M, Salhan D, Singh T, Rai P, Mathieson PW, Saleem MA, Malhotra A, Singhal PC HIV compromises integrity of the podocyte actin cytoskeleton through downregulation of the vitamin D receptor. *Am J Physiol Renal Physiol.* 2013, 304:F1347-57
10. Eckard AS, McComsey GA. Vitamin D Deficiency and Altered Bone Mineral Metabolism in HIV-infected Individuals. *Curr HIV/AIDS Rep.* 2014, 11(3): 263–270
11. Fiscella K, Winters P, Tancredi D, Hendren S, Franks P. Racial disparity in death from colorectal cancer: does vitamin D deficiency contribute? *Cancer.* 2011, 117:1061-9
12. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. *Hypertension* 2007, 49: 1063–1069
13. Han L, Zhou R, Niu J, McNutt MA, Wang P, Tong T. SIRT1 is regulated by a PPAR $\gamma$ -SIRT1 negative feedback loop associated with senescence. *Nucleic Acids Res.* 2010, 38(21):7458-71.
14. Hosseini-nezhad A, Holick MF. Vitamin D for Health: A Global Perspective. *Mayo Clin Proc.* 2013, 88(7): 720–755.

- 445 **15.** Imai S, Johnson FB, Marciniak RA, McVey M, Park PU, Guarente L. Sir2: an  
446 NAD-dependent histone deacetylase that connects chromatin silencing,  
447 metabolism, and aging, Cold Spring Harb. Symp Quant Biol. 2000;65:297–302.
- 448 **16.** Jaganath D, Mupere E. Childhood Tuberculosis and Malnutrition. J Infect  
449 Dis. 2012 December 15; 206(12): 1809–1815.
- 450 **17.** Larriba MJ, Bonilla F, Muñoz A. The transcription factors Snail1 and Snail2  
451 repress vitamin D receptor during colon cancer progression. J Steroid Biochem  
452 Mol Biol. 2010, 121(1-2):106-9.
- 453 **18.** Leri A, Liu Y, Li B, Fiordaliso F, Malhotra A, Latini R, Kajstura J, Anversa P. Up-  
454 Regulation of AT<sub>1</sub> and AT<sub>2</sub> Receptors in Postinfarcted  
455 Hypertrophied Myocytes and Stretch-Mediated Apoptotic Cell Death
- 456 **19.** Li C, Siragy HM. High glucose induces podocyte injury via enhanced (pro)renin  
457 receptor-Wnt- $\beta$ -catenin-snail signaling pathway. PLoS One. 2014, 9(2):e89233.
- 458 **20.** Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a  
459 negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002,  
460 110(2):229-38.
- 461 **21.** Mottis A, Mouchiroud L, Auwerx J. Emerging roles of the corepressors NCoR1  
462 and SMRT in homeostasis. Genes Dev. 2013 27(8): 819–835.
- 463 **22.** Patel T, Singh AK. Role of Vitamin D in Chronic Kidney Disease. Semin Nephrol.  
464 2009, 29(2): 113–121
- 465 **23.** Qiang L, Wang L, Kon N, Zhao W, Lee S, Zhang Y, Rosenbaum M, Zhao Y, Gu  
466 W, Farmer SR, Accili D. Brown remodeling of white adipose tissue by SirT1-  
467 dependent deacetylation of PPAR- $\gamma$ . Cell. 2012, 150(3):620-32
- 468 **24.** Rai P, Singh T, Lederman R, Chawla A, Kumar D, Cheng K, Valecha G,  
469 Mathieson PW, Saleem MA, Malhotra A, Singhal PC. Hyperglycemia enhances

kidney cell injury in HIVAN through down-regulation of vitamin D receptors. *Cell Signal*. 2015 Mar;27(3):460-9.

**25.** Salhan D, Husain M, Subrati A, Goyal R, Singh T, Rai P, Malhotra A, Singhal PC. HIV-induced kidney cell injury: role of ROS-induced downregulated vitamin D receptor. *Am J Physiol Renal Physiol*. 2012, 303:F503-14

**26.** Singh T, Ayasolla K, Rai P, Chandel N, Haque S, Lederman R, Husain M, Vethantham V, Chawla A, Vashistha H, Saleem MA, Ding G, Chander PN, Malhotra A, Meggs LG, Singhal PC. AT1R blockade in adverse milieu: role of SMRT and corepressor complexes. *Am J Physiol Renal Physiol*. 2015 309(3):F189-203.

**27.** Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. *Cell*. 2008;133:612–626.. *Am J Pathol*. 2000; 156: 1663–1672.

**28.** Vashistha H, Singhal PC, Malhotra A, Husain M, Mathieson P, Saleem MA, Kuriakose C, Seshan S, Wilk A, Delvalle L, Peruzzi F, Giorgio M, Pelicci PG, Smithies O, Kim HS, Kakoki M, Reiss K, Meggs LG. Null mutations at the p66 and bradykinin 2 receptor loci induce divergent phenotypes in the diabetic kidney. *Am J Physiol Renal Physiol*. 2012, 303(12):F1629-40.

**29.** Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. *Cell*. 2001;107:149–159.

**30.** Wang R, Sengupta K, Li C, Kim H, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Jia R, Zheng Z, Appella E, Wang XW, Ried T, Deng C. Impaired DNA damage



response, genome instability, and tumorigenesis in SIRT1 mutant mice. *Cancer Cell*. 2008;14:312–323.

**31.** Wang R, Sengupta K, Li C, Kim H, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Jia R, Zheng Z, Appella E, Wang XW, Ried T, Deng C. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. *Cancer Cell*. 2008;14:312–323.

**32.** Yang H, Zhang Y, Zhou Z, Jiang X, Shen A. Snail-1 regulates VDR signaling and inhibits 1,25(OH)-D<sub>3</sub> action in osteosarcoma. *Eur J Pharmacol*. 2011, 670(2-3):341-6.

**33.** Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. *Biochim Biophys Acta*. 2010, 1804(8): 1684–1689

**34.** Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, Quigg RJ, Li YC. Renoprotective role of the vitamin D receptor in diabetic nephropathy. *Kidney Int*. 2008 Jan;73(2):163-71.

**Figure legend**

**Fig. 1 Renal tissues lacking VDR display enhanced expression of p53 and activation of renin angiotensin system**

A. Protein blots of renal tissues of control (FVB/N) and VDR mutant (M) mice were probed for p53, angiotensinogen (Agt), renin, and AT1R and reprobed for actin (n=4).

Representative gels in duplicate are displayed.

B. Cumulative densitometric data (n=4) of protein blots probed for p53 and actin in the form of bar graphs.

C. Mean Agt/Actin ratio of renal tissue protein blots from control and VDR-M mice (n=4).

D. Mean Renin/Actin ration of renal tissue protein blots from control VDR mutant mice (n=4)

E. Mean AT1R/Actin ratio of renal tissues from control and VDR-M mice (n=4).

\*P<0.05 compared to respective FVB/N

**Fig. 2. VDR deficient podocytes display enhanced expression of p53 and activation of renin angiotensin system**

Podocytes were either silenced for VDR by transfecting them with siRNA-VDR (Si/VDR) or control (scrambled)-siRNA (SiCon). Protein blots of Si-Con or SiVDR (n=4) were probed for p53 and then reprobed for Agt, renin, and actin.

A. Representative gels (in duplicates) are shown.

B. Cumulative densitometric data (VDR/Actin ratios) are shown as bar graphs (n=4).

C. Mean p53/actin ratios from SiVDR and SiCon protein blots are shown as bar graphs (n=4).

D. Mean Agt/Actin ratios from SiVDR and SiCon protein blots are shown as bar graphs (n=4).

E. Mean Renin/Actin ratios SiVDR and SiCon protein blots are shown as bar graphs (n=4).

\*P<0.05 compared with respective SiCon.

### **Fig. 3. Effect of VDR silencing on podocyte Agt and renin mRNA expression**

Podocytes were transfected with either scrambled siRNA (SiCon) or siRNA-VDR (SiVDR) (n=4). cDNAs from SiCon and SiVDR were amplified with specific primers for VDR, Agt, and renin.

A. VDR mRNA expression by SiCon and SiVDR is displayed as bar graphs.

B. Agt mRNA expression by SiCon and SiVDR is displayed as bar graphs.

C. Renin mRNA expression by SiCon and SiVDR. is displayed as bar graphs.

\*P<0.05 vs. SiCon

### **Fig. 4. Lack of VDR is associated with down regulation of SIRT1 in VDR-M mice**

A. Protein blots of renal tissues (n=4) of control and VDR-M mice were probed for SIRT1 and the same blots were reprobed for GAPDH. Representative gels in duplicate are shown.

B. Protein blots of renal tissues of control (n=4) and VDR-heterozygous (h) (n=5) were probed for SIRT1 and reprobed for GAPDH. Gels are displayed.

C. Densitometric data (SIRT1/GAPDH) of protein blots of Fig. B are shown as bar graph.

\*P<0.05 compared with FVB/N

**Fig. 5. Lack of SIRT1 is associated with p53 acetylation at K382 residues in renal tissues of VDR-M mice**

A. Renal tissues of control (n=3) and VDR-M (n=3) were probed for SIRT1. The same blots were stripped and reprobed for p53, Ac<sup>k382</sup>-p53, Agt, AT1R, PPAR-γ, and GAPDH. Gels are displayed.

B. Cumulative densitometric data (variable/GAPDH ratio) are shown.

\*P<0.05 compared with respective FVB/N

**Fig. 6. Podocytes partially lacking SIRT1 from their genome display enhanced acetylation of p53 at K382 residues in podocytes**

A. Human podocytes were transfected either control (C)- siRNA or SIRT1-siRNA. Control cells, C-siRNA- and SIRT1-siRNA transfected cells were incubated in media for 24 hours. Total RNA as well as proteins was harvested. cDNAs were prepared and amplified with a probe specific for SIRT1. Results are displayed as bar graph.

B. Protein blots of control (C)- siRNA or SIRT1-siRNA. Control cells, C-siRNA- and SIRT1-siRNA transfected cells were probed for SIRT1, p53, ac-K382p53, and GAPDH. Gels are displayed.

**Fig. 7. High glucose down regulates SIRT1 in a time dependent manner**

577 A. Human podocytes were incubated in media containing either normal glucose  
578 (5 mM, control) or high glucose (35 mM) for 24 and 48 hours. Protein blots  
579 were probed for SIRT1. The same blots were reprobed for p53, Agt, and  
580 GAPDH. Gels are displayed.

581 B. Human podocytes were incubated in media containing either normal glucose  
582 (5 mM) or high glucose (35 mM) for variable time periods (4, 12, 24, and 48  
583 hours). Protein blots were probed for SIRT1. The same blots were reprobed  
584 for p53 and GAPDH. Gels are displayed.

585 **Fig. 8. Enhanced podocyte VDR expression is associated with increased SIRT1**  
586 **expression**

587 A. Podocytes were transfected with either control plasmid (pcDNA), SIRT1, or VDR. In  
588 parallel sets of experiments podocytes were incubated in media containing VDR agonist  
589 (VDA, EB1089, 1 nM) for 24 hours. Protein blots were probed for SIRT and reprobed  
590 for GAPDH. Gels are displayed.

591 B. Podocytes were incubated in media containing VDA (EB1089, 1 nM) for variable time  
592 periods (0, 2, 4, 8, 12, 24 hours). Protein blots were probed for SIRT1 and reprobed for  
593 GAPDH. Gels are displayed.

594 **Fig. 9. Proposed scheme**

595 Lack of VDR in podocytes induces down regulation of SIRT1, which enhances podocyte  
596 p53 expression through allowing acetylation of p53. Enhanced p53 expression induces  
597 transcription of Agt and AT1R leading to the activation of the RAS.

598 **Fig. 10. Unliganded VDR complements liganded VDR-mediated renin transcription**  
599 **in vitamin D deficient state**

600 Vitamin D deficient state lacks both liganded and unliganded VDR. Lack of liganded  
601 VDR would enhance the transcription of renin, whereas, lack of unliganded VDR would  
602 stimulate the transcription of angiotensinogen and AT1R. Unliganded VDR-induced  
603 AT1R activation should down regulate renin gene expression; however, this negative  
604 feedback effect of AT1R activation would be neutralized because of deficient liganded  
605 VDR-stimulated renin transcription.








Fig. 1




Fig. 2








Fig. 3






Fig. 4





Fig. 5



**A****B**

Fig. 6



**A****B**

Fig.7




Fig. 8




Fig. 9




Fig. 10